Liquidia Corp - Earnings Call - Q1 2025

Executive Summary

• Q1 2025 revenue of $3.12M and EPS of -$0.45 declined year over year and missed Street estimates (Rev: $3.23M; EPS: -$0.40); operating loss was -$35.4M as commercialization prep ramped ahead of YUTREPIA launch. Estimates from S&P Global.
• Management highlighted no current legal barriers to final FDA approval following expiration of Tyvaso DPI exclusivity on May 23; FDA accepted the NDA resubmission on Mar 28, and YUTREPIA received approval on May 23, 2025, creating an immediate commercialization catalyst.
• Cohort A of the ASCENT PH-ILD study fully enrolled (>50 patients); early data suggest rapid up-titration and tolerability with positive 6-minute walk trends, supporting differentiation versus incumbent formulations.
• Balance sheet cash was $169.8M at quarter-end; Liquidia amended its HCR agreement to access up to $100M incremental funding to support launch and pipeline programs.
• Post-quarter, UTHR filed a new patent complaint (‘782), seeking to enjoin commercialization; Liquidia emphasized this does not impact FDA’s ability to approve and is preparing to defend commercialization plans.

What Went Well and What Went Wrong

What Went Well

• YUTREPIA regulatory momentum: FDA accepted the Class 1 resubmission with a May 24 PDUFA date; final approval was granted May 23, unlocking the launch path.
• Clinical execution: ASCENT Cohort A fully enrolled (>50 PH-ILD patients) with tolerability and titratability consistent with INSPIRE; patients titrated to doses ~3x higher than nebulized Tyvaso labeled target, with positive trends in 6MWD.
• Commercial readiness: Sales force (~50 reps) and medical affairs team in place; product availability planned in-channel 2–3 weeks post-approval; payer access strategy emphasized.
  • CEO: “we are proud to say there continue to be no legal barriers barring YUTREPIA's potential final approval following the expiration of gating regulatory exclusivity on May 23, 2025”.

What Went Wrong

• Financial pressure: G&A rose 48% YoY to $30.1M with higher headcount, legal fees, and infrastructure; net loss widened to -$38.4M and other expense increased on higher HCR borrowings.
• Top-line softness: Revenue of $3.12M modestly increased YoY (+$0.15M) but missed consensus ($3.23M), reflecting lower sales volumes in the Treprostinil Injection promotion and gross-to-net dynamics. Estimates from S&P Global.
• Ongoing litigation risk: UTHR’s May 9 ‘782 patent complaint seeks to block commercialization despite FDA approval; TRO/PI motion was argued May 20 and remains pending, injecting launch uncertainty.

Transcript

Operator (participant)

Good morning and welcome, everyone, to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded. I will now hand the call off to Jason Adair, Chief Business Officer.

Jason Adair (Chief Business Officer)

Thank you, Operator. It is my pleasure to welcome everyone to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Call. Joining the call today are Chief Executive Officer Dr. Roger Jeffs, Chief Medical Officer Dr. Rajeev Saggar, Chief Operating Officer and CFO Michael Kaseta, Chief Commercial Officer Scott Moomaw, and General Counsel Rusty Schundler. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements.

These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call.For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I would now like to turn the call over to Roger for our prepared remarks, after which he will open the call for your questions.

Roger Jeffs (CEO)

Good morning, everyone, and thank you for joining us today. In a little more than two weeks, May 24th to be precise, we will have reached the PDUFA goal date for Liquidia's first internally developed commercial product, YUTREPIA, an investigational inhaled dry powder formulation of Treprostinil for the treatment of pulmonary arterial hypertension, or PAH, and pulmonary hypertension associated with interstitial lung disease, or PH-ILD. With all eyes on the future, we are going to keep our prepared remarks focused on a few key areas. First, I'd like to take a moment to highlight last week's news regarding the decision rendered by the District Court

dismissing United Therapeutics' cross-claim that sought to challenge our amendment to the new drug application for YUTREPIA, which added the treatment of PH-ILD to YUTREPIA's proposed label.While United Therapeutics has the right to appeal the court's ruling, we are pleased with the court's decision to dismiss this cross-claim, specifically holding that United Therapeutics failed to establish standing. We are proud to say there continue to be no legal barriers barring YUTREPIA's potential final approval following the expiration of gating regulatory exclusivity on May 23rd, 2025.

With this favorable ruling in hand, we are doubling down on our preparations for the potential launch of YUTREPIA, with a laser focus on five key strategic areas. First, we're developing what we believe is a best-in-class product profile for YUTREPIA. As we've said before, YUTREPIA's tolerability, titrateability, ease of use, and future labeling speaks to the fact that it offers a differentiated product profile. We continue to further characterize these clear benefits in the company's open label Ascend study in PH-ILD patients.As communicated in this morning's press release, Cohort A of the Ascend study is now fully enrolled with more than 50 patients.

The interim data has shown us that the dosing and tolerability profile in the first 20 patients to complete eight weeks of treatment was consistent with observations made in the Inspire study of PAH patients. Thus far, PH-ILD patients in the Ascend study have been able to titrate to doses that are three times higher than the labeled target dose of nebulized Tyvaso. These patients have also shown positive trends on exploratory measures of efficacy, including Six-minute walk distance. Additional data from the Ascend study will be presented during two poster sessions at the American Thoracic Society International Conference in San Francisco on May 20th.

As part of the Ascend study, we will begin Cohort B, a directed transition study in the coming months where we will take patients unsatisfied with the clinical attributes of Tyvaso and Tyvaso DPI and transition them to YUTREPIA. The goal of this study will be to directly compare the differences and potential benefits that YUTREPIA presents, both in PAH and PH-ILD patients. You'll hear more regarding this study in the months ahead. Next, we are fully prepared to go to market with a competitive share of voice. We have 50 sales reps in the field who have been on board for about 18 months and a companion medical affairs team,

all with an impressive level of rare disease experience and most with PH experience. These groups have been actively surveilling both the major centers of excellence as well as the community prescriber base in preparation for YUTREPIA's potential launch. Our third strategic area of focus is our preparation to launch a full suite of patient support services, which we have meticulously put into place. Physicians and patients should expect no differences in support with YUTREPIA, whether starting inhaled Treprostinil for the first time or transitioning from incumbent inhaled products. Fourth, we have continued to focus on ensuring robust product availability.

Mike and his team at Liquidia have prepared to put product in the channel in only two to three weeks after YUTREPIA's potential approval. Finally, the fifth strategic area of focus that will help us ensure success is broad payer access. Over the last several years, we have developed strong relationships with payers who understand the differentiated product profile that YUTREPIA can offer to patients. We remain confident that patients will have access to YUTREPIA within a short time after launch. With all these in play, we feel well prepared to launch YUTREPIA

into the marketplace once approved, and we look forward to fulfilling our promise to provide patients with PAH and PH-ILD a much-needed and potentially best-in-class therapeutic alternative. I'll now turn the call over to Mike to provide an overview of our first quarter 2025 financials. Mike.

Michael Kaseta (COO and CFO)

Thank you, Roger, and good morning, everyone. Turning to our first quarter 2025 financial results, which can be found in the press release, you will see that revenue was $3.1 million for the three months ended March 31, 2025, compared to $3 million for the three months ended March 31, 2024, revenue related primarily to the promotion agreement. The increase of $0.1 million was primarily due to the impact of unfavorable gross-to-net returns adjustments recorded in the prior year, offset by lower sales volumes in the current year. Cost of revenue was $1.5 million for each of the three months ended March 31st, 2025, and 2024, cost of revenue related to the promotion agreement as noted above. Research and development expenses were $7 million for the three months ended March 31st, 2025, compared to $10.1 million for the three months ended March 31st, 2024.

The decrease of $3.1 million, or 31%, was primarily due to a $3.6 million decrease in personnel expenses, including staff-based compensation, due to a shift from activities related to research and development to preparation for the potential commercialization of YUTREPIA. These decreases were offset by a $1.7 million increase in clinical expenses related to our L606 program and a $0.4 million decrease in expenses related to our YUTREPIA research and development activities. General and administrative expenses were $30.1 million for the three months ended March 31st, 2025, compared to $20.2 million for the three months ended March 31st, 2024.

The increase of $9.9 million, or 48%, was primarily due to an $8.1 million increase in personnel expenses, including stock-based compensation, driven by higher headcount and a shift from activities related to research and development to preparation for the potential commercialization of YUTREPIA, a $0.6 million increase in legal fees related to our ongoing YUTREPIA-related litigation, and a $0.6 million increase in facilities and infrastructure expenses. We incurred a net loss for the quarter ended March 31, 2025, of $38.4 million, or $0.45 per basic and diluted share, compared to a net loss of $30.1 million, or $0.40 per basic and diluted share for the three months ended March 31, 2024. Included in the comparative results we have presented is an immaterial revision of other income, as previously reported for fiscal year 2024.

This revision is a technical non-cash accounting adjustment related to gain and loss recognized when we made amendments to our HCRx facility made in 2024. Additional details are included in the Form 8K we filed this morning. I would now like to turn the call back over to Roger.

Roger Jeffs (CEO)

Thank you, Mike. In summary, we continue to drive forward the right set of strategies to support the successful potential launch of YUTREPIA in the coming weeks, and we look forward to providing both physicians and patients with what we believe could soon become the prostacyclin of first choice. I would now like to open the call to questions. Operator, first question, please.

Operator (participant)

Thank you. At this time, we will conduct the question-and-answer session. As a reminder, to ask a question, you will need to press star one,one on your telephone and wait for your name to be announced. To withdraw your question, please press star one,one again. Our first question comes from the line of Julian Harrison of BTIG. Your line is now open.

Julian Harrison (Managing Director)

Hi, congrats on all the progress, and thank you for taking my questions. I'm wondering if you believe United has any injunctive value left on the cross-claim that was dismissed last week. Also curious if you had any reaction to the dismissal without prejudice versus with prejudice, given the judge's express views on standing and the opinion memorandum.

Roger Jeffs (CEO)

Good morning, Julian. Good to hear from you. Rusty, if you wouldn't mind answering Julian's two questions.

Rusty Schundler (General Counsel)

Sure. Julian, thanks for the question. Let me, I mean, go over a couple of things. One, what's absolutely clear is that there's currently no proceeding actively ongoing in which United Therapeutics is seeking to enjoin either the FDA from giving us approval for YUTREPIA or seeking any sort of temporary restraining order or preliminary injunction to prevent our launch of YUTREPIA upon approval. That's number one. Number two, the dismissal was without prejudice. Again, keep in mind it was a motion to dismiss, so the judge was not addressing the full merits of the case. This was a question of whether their complaint had even set forth grounds upon which the court could even entertain their lawsuit.

What that does mean is they can try to repurpose or refashion the argument in the future, but I think what's clear from the way in which he approached the opinion is they can't come back with the exact same argument they did before. I think they still have significant standing issues trying to link the bundling guidance to a 30-month stay. Keep in mind, again, this is all just at the motion to dismiss phase. They still would have to then show that they're correct on the merits as well. As far as other things that United Therapeutics might do, which I think your question alluded to, that's really not for us today. We don't know what lengths they're going to go to try to deny PAH and PH-ILD patients access to an alternative therapy.

What I can say, though, is we'll be ready in whatever form they pursue something. If they pursue anything from here on out, we'll be ready to address it. Thanks.

Julian Harrison (Managing Director)

Excellent. Very helpful. Thank you, and congrats again.

Roger Jeffs (CEO)

Thank you, Julian. Next question, please.

Operator (participant)

Thank you. Our next question comes from the line of Kambez Yazdi of Jefferies. Your line is now open. Kambez, do we have you here?

Kambez Yazdi (VP of Biotech Equity Research)

Sorry. Morning, team. Thank you so much for the questions and very exciting times for the company. Maybe a little bit on the forward-looking transition studies. Any kind of thoughts on what may be interesting patient baseline characteristics that you may be looking to enroll in that study and then would love to get an update on L606 as well?

Roger Jeffs (CEO)

Great. Both of those questions fall into Rajeev Saggar's court. Rajeev, do you mind answering those?

Rajeev Saggar (Chief Medical Officer)

Yeah, hi Kambez. Thanks for the question. The first question was regarding the upcoming transition study. This study is specifically evaluating the transition from Tyvaso, either nebulized and preferably dry powder inhaler, to YUTREPIA. These patients will be specifically in the category of PH-ILD. That is very purposeful. As you know, for our NDA filing in the Inspire study, we already showed that we were able to successfully transition patients with group 1 PAH from nebulized Tyvaso directly to YUTREPIA. Now we are trying to do the same thing in the PH-ILD population. First of all, these patients will be on background Tyvaso. Let's assume the majority of them are on dry powder inhaler. These patients will have PH-ILD.

Very similar to Cohort A in part of the Ascend study that we are presenting at ATS, we are going to be looking for the ability to—we are going to be looking at safety. Can we safely transition? Number two, can we transition them and then continue to showcase our product profile, which we believe is going to be beneficial in terms of our ability to up-titrate that patient, maintain their clinical stability, or even improve them? We will be looking at exploratory efficacy modalities, inclusive of, of course, Six-minute walk and other quality-of-life indicators. We look forward to showcasing that study and initiating that in the next few months. In your second question, Kambez, is that on L606?

Kambez Yazdi (VP of Biotech Equity Research)

Yeah, just an update there.

Rajeev Saggar (Chief Medical Officer)

Yeah, thank you. We're working diligently to initiate this global study. Just to recap, this is the liposomal sustained-release formulation of Treprostinil that we're going to be delivering twice a day. Just to recap, this is a global study with more than 300 patients and more than 20 companies. We anticipate that we'll be initiating this study by year's end.

Kambez Yazdi (VP of Biotech Equity Research)

Thank you.

Operator (participant)

Thank you. Our next question comes from the line of Greg Harrison of Scotiabank. Your line is now open.

Greg Harrison (Director of Biotechnology)

Hey, good morning, guys. Congrats on the progress, and thanks for taking the question. We have seen the competitors struggle to convert patients to their dry powder formulation, and their nebulized formulation has persisted longer than thought initially. Could you speak to the patient perspective on switching to dry powder formulation and whether you think YUTREPIA will have a stronger case for keeping patients on a DPI formulation than we have seen with Tyvaso? How do you think the Ascend data will help with this argument?

Roger Jeffs (CEO)

Yeah, good morning, Greg. Thanks for the question. I'll start with an answer, and then Rajeev, if you'll give your thoughts as well, I think that'd be helpful. I think you are right. It's surprising that there remain residual nebulized Tyvaso patient base. I think it's about 31% of the scripts today. When all thoughts, including the competitors' thoughts initially, were that all patients would transition to the DPI for portability reason alone. That hasn't happened, and the question is why. We think it's formulation-driven in that their formulation is part of an aggregated polydispersed formulation on an FTKP backbone. Really, in a high-resistance device and low flow, it really doesn't deliver the drug to the lower airway, which is the site of action.

That's completely the opposite of what a print-enabled YUTREPIA is going to achieve, and which is what we've shown in the Ascend study, that patients can tolerate the drug well, they can get to very high doses, and they can get there quickly. Those two points are important in the sense that patients want to feel better. They want to do it on a convenient and portable therapeutic modality. We think YUTREPIA is clearly defined as a differentiated and a better opportunity to do just that. I think what we'll do in the marketplace first is go after new patient starts to let physicians experience the benefits of YUTREPIA firsthand. Once they're comfortable with that,

then we'll see if they will transition, particularly their nebulized patients who are going to be looking for an alternative, more portable therapy. I think it becomes a question of, would you even start Tyvaso DPI? Or if you're on Tyvaso DPI, would you want to transition? As Rajeev just said in the previous question, we're going to have data directing to the specifics of how you transition and the benefits of doing the same. We're really excited about all of the market opportunity, but I do agree that the nebulized Tyvaso retained commercial share is at risk, and we're certainly going to go after that in time. Rajeev, do you have any thoughts?

Rajeev Saggar (Chief Medical Officer)

Yeah, thanks, Roger. I think, again, just highlighting, I think we believe in our scientific formulation and our hypothesis that the PRINT formulation with the low-flow resistance device is actually what these patients need. I think from my perspective, I think what's really unique is two things. Back when we did the Inspire study in group 1 PAH, it took a while for patients to titrate up YUTREPIA to get to doses of therapeutic zones. I think what we're seeing now, a few years later, now that we did the first cohort study that we now have fully enrolled and we're going to showcase that data at ATS, is that not only can we titrate doses to above the sort of

traditional 9-12 breaths, we're dosing these to at least two full levels higher than what traditionally is given by Tyvaso.We can do it in a matter of just several weeks, not over a course of a year. I think that's very important because these patients are extremely sick. They are susceptible to clinical worsening. Finally, inherently, they just have terrible coughs. One thing, I think, to your question is that the current incumbent's dry powder formulation, I think one of its major limitations is its inability to titrate to the appropriate doses to match the clinical severity of the patient, in part due to cough. I think one of the things that we are going to continue to highlight, especially at ATS,

is just the tolerability profile of YUTREPIA seems to be well-received by the patients and the practitioners that are participating in the study. I think using that signal and re-showing that in the transition study, I think, would be well-received by the scientific community.

Roger Jeffs (CEO)

Great. Thank you, Rajeev. I think your comments speak to the snippets of why we're so excited about the pending launch. Operator, next question, please.

Operator (participant)

Thank you. Our next question comes from the line of Cory Jubinville of LifeSci Capital. Your line is now open.

Cory Jubinville (Managing Director)

Thanks for taking our questions and congrats on the progress. You mentioned earlier in the prepared remarks that you're building out this prescriber support team. As we speak to KOLs, in addition to efficacy and tolerability, it seems that ease of prescribing also appears to be a major component to their prescription habits. Could you just provide a little bit more detail as to what that support team might look like and their activities? Specifically, what might you be doing that improves the prescriber experience over what's out there presently and how that compares to potential competitors? I guess on the patient side, in terms of early patient access, do you have any details about what a potential bridging program might look like if that's in the plans for patients?

Roger Jeffs (CEO)

Yeah, thanks for the question, Cory. We're benefiting by having our Chief Commercial Officer, Scott Moomaw, on the call. Scott, if you wouldn't mind addressing the questions.

Scott Moomaw (CCO)

Yeah, sure. Good morning. The specifics, I think, we'll sort of share as we get through and pass approval around the patient support program. What I would say is our team has over a decade—most folks have over a decade of experience with Treprostinil and the various forms, working with specialty pharmacies, working with this patient population. We have a very good understanding of what the needs of the HCPs and the patients are. We have built out a program that we think, in all respects, will be as good as or better than what's on the market right now in terms of the way that these patients have been cared for. We completely understand the point that you raised around

being able to start these patients is what's very important to early success. We are going to make sure that we have everything in place to make sure that happens. We look forward to sharing that with you, hopefully after the end of May.

Roger Jeffs (CEO)

Great. Thank you, Scott.

Operator (participant)

Thank you. Our next question comes from the line of Jason Gerbery of BofA. Your line is now open.

Chi meng Fong (VP and Equity Research Analyst)

Hey, guys. This is Chi on for Jason. Thanks for taking our question. You have some data presentation at the ATS meeting in a couple of weeks. I'm curious if you can give us an early flavor of these presentations, what's your expectations, and when might we get the full 48-week data from the Ascend study? Thanks so much.

Roger Jeffs (CEO)

Great. Since Rajeev, you're the leading architect of the Cohort A study, if you could talk to that question.

Rajeev Saggar (Chief Medical Officer)

Yeah, thanks for that question. I think at this point, obviously, we're under embargo to go into the actual details of the study. Essentially, we're going to be presenting three posters. Two are specifically related to the Ascend study, which will showcase the first 20 patients that were treated for eight weeks. Remember, these are patients with newly diagnosed PH-ILD that are now taking YUTREPIA. We'll showcase a few things, the baseline demographics. We will detail out the tolerability profile of these patients as well as the dosing characteristics that we're seeing. That's the first thing. The second thing is that we'll finally showcase some exploratory endpoints within the first two posters.

The first one being, of course, what happens to their exercise tolerability, which is defined by the Six-minute walk distance compared to baseline through eight weeks. The other thing is we're going to showcase a novel endpoint that's known as cardiac effort. That will be presented by Dr. Dan Lachant at the University of Rochester. Again, sort of understanding why potentially these patients are showing improvements in their exercise capacity and what are the potential reasons for that and how YUTREPIA is modifying its performance on the right ventricle. The third poster will be presented looking at transitioning a patient that was participating in the Inspire study who had acutely worsened and was hospitalized, placed on intravenous

Treprostinil, and transitioned to LIQ861 or YUTREPIA, and just highlighting that safety, that ability to transition patients from parenteral therapy back to LIQ861 in that study. All in all, we're very excited to, again, showcase some of these, our product profiles at ATS.

Roger Jeffs (CEO)

Thank you, Rajeev. Obviously, the timing of that data is quite exciting and the fact that it will be presented literally within a week of potential approval. Operator, next question.

Chi meng Fong (VP and Equity Research Analyst)

Great. Thank you.

Operator (participant)

Thank you. Our next question comes from the line of Serge Belanger of Needham. Your line is now open.

Serge Belanger (Analyst)

Hi, good morning. A couple of commercial questions. The first one maybe for Roger and Scott. Can you just describe the level of awareness of YUTREPIA and its differentiating attributes in the group of physicians you'll be targeting upon launch? Secondly, do you expect that there could be some warehouse demand for this product, or is this a group of physicians that will likely want to run their own internal evaluation before really ramping up usage of YUTREPIA? Thanks.

Roger Jeffs (CEO)

Yeah, thanks for the question, Serge. Scott, maybe if you could opine on this.

Scott Moomaw (CCO)

Sure. On the awareness question, obviously, prior to launch, we're very limited in what we can communicate from a commercial perspective. In fact, nothing. We are looking forward to the launch. I can guarantee you that we will be loud. The awareness will go up extremely quickly. There is background awareness due to the medical information we've shared, etc. Once the sales team gets out there, we have a full suite of marketing activities, electronic activities. Our goal is that every HCP who is involved in PH, whether that be PAH or PH-ILD, will be aware and will be able to try it very soon after launch.

The second question was about warehousing. I think there might be some of that due to the tolerability issues in the conversation that came up earlier around the nebulized patients.Certainly, as Roger has said, I think even earlier in this call, we'll be focused on new patients because those are the patients that give the physician really the best opportunity to try the drug in sort of a clean way. Having said that, we have heard from a number of physicians that they have patients that have transitioned back to the nebulized version of Tyvaso. I think we all understand that that's not optimal from a convenience standpoint and a dosing standpoint.

We will get some of those. We will work with those physicians to make sure that those are successes. Strategically, the patients that we will be going after, first and foremost, will be those patients that are new to prostacyclines.

Roger Jeffs (CEO)

Yeah, thanks. I think, Serge, one way to look at this is there's been almost three phases of how we integrate YUTREPIA into the standard of care. I do think we can change the paradigm that currently exists and become the prostacyclin of first and best choice. I think we'll do the new patient starts, then we'll do the transitions. If you just said what's the current inhaled Treprostinil market, that's a $2 billion market opportunity and growing significantly still with the sort of white space that remains in PH-ILD. The other $2 billion today market opportunity is the oral prostacyclins, both of Tyvaso and Orenitram, enjoy.

I don't think there's been any counter-detailing against those products to date. We certainly are going to do that because they have significant off-target effects.There's quite some duress that the patients have to undergo to get to therapeutic doses and be maintained on those therapies that we think we can solve for because now, for the first time, there's a readily titratable and durable inhaled prostacyclin called YUTREPIA. Those different promotional cadences will happen at different paces. I think collectively, we're going to integrate ourselves across all of that. When you look at what's the current market opportunity, it's really $4 billion and growing.

I think there's opportunity for us to be very successful. We don't necessarily need to take incumbent share, but I think over time, that will happen. Operator, maybe one more question if you have any.

Operator (participant)

Thank you. Our last question comes from the line of Ryan Deschner of Raymond James. Your line is now open.

Ryan Deschner (VP of Equity Research)

Good morning. Curious on what you're anticipating in terms of the split between commercial and public payers in PAH and PH-ILD. Was wondering if you could just quickly walk us through the important points of the 494 patent infringement suit that you recently filed. Thank you.

Roger Jeffs (CEO)

Yeah. Scott, if you'll answer the first part of that, and then Rusty, you'll talk about the 494 litigation.

Scott Moomaw (CCO)

Yeah. From a payer standpoint, looking at the prostacyclin market and Tyvaso specifically, we think we'll probably have about 50% Medicare, about 35% commercial, maybe 10% Medicaid, and then 5% other, whether that be Tricare, DOD, etc. We will see when we get out there, but that seems to be what we're expecting.

Rusty Schundler (General Counsel)

Ryan, thanks for the question on the 494 lawsuit. We are not really going to comment much on that. I mean, obviously, we filed the lawsuit. I think the complaint sets forth pretty clearly our thoughts as to the grounds on which we are proceeding with an infringement lawsuit. That case is in the very early stages. We cannot really comment on timing and, typical with best practice, will not comment publicly on legal theories or legal strategies we are going to pursue in the case.

Great. Thank you, Scott.

Scott Moomaw (CCO)

Thank you.

Roger Jeffs (CEO)

Thank you, Ryan, for the question.With that, we will close. As you can see, we are very excited about actually matriculating our mission and vision of delivering a new treatment modality to patients with PH and PH-ILD. Hopefully, as May 24th approaches, we will be in touch and speaking with you all very soon.Thank you for your time this morning.

Operator (participant)

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.